Inclusion Criteria:  Diagnosed with new-onset MI, either STEMI or NSTEMI, according to the fourth universal definition of MI (Thygesen et al. 2019), disease onset within 7 days. Patients are previously diagnosed with essential hypertension or newly diagnosed with essential hypertension. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and the protocol.  Exclusion Criteria:  Patients with severe renal dysfunction. (GFR<60mmol/L). Patients who have recently undergone immunosuppressive therapy. Patients who are known to be allergic to Sacubitril/Valsartan and Valsartan. Patients who are hemodynamically unstable. Chronic symptomatic heart failure within the last year and known reduced ejection fraction (LVEF≤40 %). Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the trial. Any non-CV condition, such as active malignancy requiring treatment at the time of screening, or severe diseases with a life expectancy of fewer than two years based on the investigator´s clinical judgment. Currently on treatment with Sacubitril/Valsartan or an ACEI/ARB.